Proteon logo     Print Page | Close Window

SEC Filings

424B3
PROTEON THERAPEUTICS INC filed this Form 424B3 on 08/21/2017
Entire Document
 
 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This prospectus and each prospectus supplement, including the documents that we incorporate by reference, contains or may contain forward-looking statements as that term is defined in the federal securities laws. The events described in forward-looking statements contained in this prospectus, including the documents that we incorporate by reference, may not occur. Generally, these statements relate to our business plans or strategies, projected or anticipated benefits or other consequences of our plans or strategies, financing plans, projected or anticipated benefits from acquisitions that we may make, or projections involving anticipated revenues, earnings or other aspects of our operating results or financial position, and the outcome of any contingencies. Any such forward-looking statements are based on current expectations, estimates and projections of management. We intend for these forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements. Words such as “may,” “expect,” “believe,” “anticipate,” “project,” “plan,” “intend,” “estimate,” and “continue,” and their opposites and similar expressions are intended to identify forward-looking statements. We caution you that these statements are not guarantees of future performance or events and are subject to a number of uncertainties, risks and other influences.

 

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to:

 

  · the timing of completing enrollment or releasing data or results of our ongoing and planned clinical trials for vonapanitase (formerly PRT-201);  
  · our estimates regarding the amount of funds we require to complete our Phase 3 clinical trial for vonapanitase;
  · our interpretation of the data from our completed Phase 2 and Phase 3 clinical trials for vonapanitase;
  · whether and when we may submit a Biologics License Application or a supplemental Biologics License Application;
  · whether we will need to conduct any additional studies after our Phase 3 trials;
  · our estimates regarding the amount of funds required to fund operations into the fourth quarter of 2019;
  · our plans to fund our chemistry, manufacturing and controls;
  · our estimates regarding expenses, future revenues, capital requirements, the sufficiency of our current and expected cash resources and our need for additional financing and plans for additional financing;
  · our estimate of when we will require additional funding;
  · our plans to commercialize and bring vonapanitase to market;
  · the timing of, and our ability to obtain and maintain, regulatory approvals for our product candidates, including vonapanitase;
  · the rate and degree of market acceptance and clinical utility of any approved product candidate and the general market for the prevention of vascular access failure;
  · our ability to quickly and efficiently identify and develop additional product candidates;
  · our search for additional product opportunities;
  · our commercialization, marketing, distribution and manufacturing capabilities, strategy and expenses;
  · plans to initiate or continue Phase 1 or Phase 1/2 trials in symptomatic peripheral artery disease or other indications; and
  · our plans to improve existing, and implement new, systems to manage our business.

 

You should also consider carefully the statements set forth in the section titled “Risk Factors” or elsewhere in this prospectus and the documents incorporated or deemed incorporated herein by reference, including but not limited to the risks described in under “Risk Factors” and elsewhere in our most recent Annual Report on Form 10-K and in our updates to those risk factors in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and other factors described elsewhere in this prospectus. Any one or more of these uncertainties, risks and other influences could materially affect our results of operations and whether forward-looking statements made by us ultimately prove to be accurate. Our actual results, performance and achievements could differ materially from those expressed or implied in these forward-looking statements. Except as otherwise required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise.

 

8